Skip to main content
. 2021 Dec 16;13(24):6320. doi: 10.3390/cancers13246320

Figure 3.

Figure 3

Multiple administrations of NSC-CRAd-S-pk7 prolong survival of immunocompetent mice bearing syngeneic glioma orthografts. Immunocompetent mice bearing orthotopic GL261 tumors were treated with NSC-CRAd-S-pk7 for 1 or 3 rounds. PFCNS + 2% HSA was used as a sham control. (A) Kaplan-Meier plot from pilot study (n = 5–6). (B) Kaplan-Meier plot from powered study (n = 11/group). Improved survival seen of mice treated with 3 rounds of NSC-CRAd-S-pk7 (3/11 alive at day 90) vs. 1 round (0/11 alive at day 90); p = 0.0067 when comparing 1 vs. 3 treatments (log-rank test). (C) Pilot clinical chemistry evaluation of repeated NSC.CRAd-S-pk7 administrations. On day 28, blood samples were collected from select mice in pilot study and assayed for the following parameters: albumin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, total bilirubin, blood urea nitrogen, calcium, phosphorus, creatine, glucose, sodium, potassium, total protein, and globulin. (D) Post-treatment mouse weights: each measurement is that of an individual mouse normalized to its initial weight on day 0 (WD/W0 × 100% where D is the day post-tumor injection).